Pharmaceutical 444731-52-6 Durable Pazopanib Intermediate Pazopanib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Pazopanib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• Purity: >99%
• Product Name: Pazopanib
• Name: Pazopanib Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: HPLC99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• CAS No.: 444731-52-6
• Mf: C21h23n7o2s.Clh
• MW: 473.987
• Density: 1.40
• Melting Point: 285-289
• Boiling Point: 728.8
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical 444731-52-6 Durable Pazopanib Intermediate Pazopanib

Product Description

Product Details

Product Name	Pazopanib
Appearance	White Powder
CAS No.	444731-52-6
MF	C21h23n7o2s.Clh
MW	473.987

Pazopanib is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply.   it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment.

Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity.      Pazopanib selectively inhibits vascular endothelial receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived  receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.

Application&Function

Pazopanib is an oral multi-target tyrosine kinase inhibitor that can block various receptors including VEGFR1-3, PDGFR - α, PDGFR - β, and c-KIT. Its mechanism of action is very similar to sorafenib and sunitinib
Indications for Pazopanib:
FDA approved for use in patients with advanced kidney cancer.
2. FDA approval for advanced soft tissue sarcoma (STS) patients who have previously received chemotherapy. However, the therapeutic effect on fatty STS or gastric stromal tumors has not yet been determined. Trial data for the treatment of soft tissue sarcoma: Phase III clinical trial

Specification